Publication date: 2018-06-07 04:39
Diarrhoea occurs in up to 75% of patients it may commence during treatment or may be delayed until some time after therapy has been completed. This may progress to colitis, including pseudomembraneous colitis (see section ), which may have life-threatening complications. Fatalities have been reported.
Clindamycin injection is injected into a muscle, or as an infusion into a vein. A healthcare provider will give your first dose and may teach you how to properly use the medication by yourself.
Antagonism has been demonstrated between clindamycin and erythromycin in vitro. Due to possible clinical significance, the two drugs should not be administered therefore clindamycin should not be given in combination with macrolides or streptogramin antibacterial agents.
Antagonism has been demonstrated between clindamycin and erythromycin in vitro. Because of possible clinical significance the two drugs should not be administered concurrently.
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. It should be used with caution, therefore, in patients receiving such agents.
Clindamycin is excreted in human milk. If possible, mothers should stop breast-feeding during therapy. Diarrhoea, fungus infection of the mucous membranes or other serious adverse events could occur in the breast-fed infant, so that nursing might have to be discontinued. The possibility of sensitivity should be borne in mind.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN HCl, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon , leading to overgrowth of C. difficile.
Clindamycin is active against gram positive organisms ( Staphylococcus aureus , Staphylococcus epidermidis, streptococci and proprionibacterium ) and gram negative organisms (bacteroides species). Susceptible organisms include both aerobic and anaerobic bacteria.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V